{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011882","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.025886+00:00","generated_at":"2026-05-17T13:58:25.963621+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering","bullets":["Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.","GAAP net loss $7.9M ($0.08 EPS); non-GAAP adjusted loss $9.9M ($0.10 EPS).","Ended Q2 with $31.1M cash after $16.1M public offering; runway extended into 2026.","Medicare contractor advisory committee meeting scheduled September 4 for EsoGuard coverage.","Partnered with Hoag for esophageal precancer testing; joined Russell 2000/3000 indexes."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011882","json":"https://secwatch.observer/filing/0001493152-25-011882.json","markdown":"https://secwatch.observer/filing/0001493152-25-011882.md","text":"https://secwatch.observer/filing/0001493152-25-011882.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/0001493152-25-011882-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315225011882/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:25.963621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}